1. Home
  2. ZWS vs TGTX Comparison

ZWS vs TGTX Comparison

Compare ZWS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zurn Elkay Water Solutions Corporation

ZWS

Zurn Elkay Water Solutions Corporation

HOLD

Current Price

$47.74

Market Cap

8.4B

Sector

Industrials

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$56.07

Market Cap

7.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZWS
TGTX
Founded
1900
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4B
7.9B
IPO Year
2008
2008

Fundamental Metrics

Financial Performance
Metric
ZWS
TGTX
Price
$47.74
$56.07
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$53.67
$49.80
AVG Volume (30 Days)
650.6K
1.9M
Earning Date
04-21-2026
05-04-2026
Dividend Yield
0.86%
N/A
EPS Growth
25.00
1746.67
EPS
0.35
0.17
Revenue
$1,530,500,000.00
$2,785,000.00
Revenue This Year
$6.90
$49.08
Revenue Next Year
$5.13
$26.69
P/E Ratio
$136.16
$337.06
Revenue Growth
19.40
N/A
52 Week Low
$43.06
$26.76
52 Week High
$55.00
$59.30

Technical Indicators

Market Signals
Indicator
ZWS
TGTX
Relative Strength Index (RSI) 41.32 63.39
Support Level $45.92 $51.22
Resistance Level $48.54 $58.04
Average True Range (ATR) 0.88 2.67
MACD -0.32 0.57
Stochastic Oscillator 27.86 88.26

Price Performance

Historical Comparison
ZWS
TGTX

About ZWS Zurn Elkay Water Solutions Corporation

Zurn Elkay Water Solutions Corp is a growth-oriented, pure-play water management business that designs, procures, manufactures, and markets the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. Its product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products, and filtered drinking water products for public and private spaces that deliver superior value to building owners, positively impact the environment and human hygiene and reduce product installation time.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: